Novo Nordisk ($NVO) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk recently completed a study titled ‘Efficacy ...
The FDA has approved semaglutide, a drug used to treat type 2 diabetes, for obesity management. Evidence suggests it can help people lose weight by suppressing appetite, as long as they keep taking it ...
Share on Pinterest New research suggests that the oral version of semaglutide, the active ingredient in injectable drugs like Ozempic, may also help treat diabetes and heart disease. Image credit: ...
Semaglutide, a GLP-1 receptor agonist (RA), was associated with a significantly lower risk for adult-onset epilepsy in patients with diabetes than other glucose-lowering drugs (GLDs). Notably, this ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The first trial of semaglutide in patients with type 1 ...
A recent study points to a potential link between GLP-1 drugs and its ability to reduce risk of epilepsy in people with type 2 diabetes. GLP-1 drugs (semaglutide) are those which mimic the function of ...
One study found that semaglutide helps to improve liver health in people with metabolic dysfunction-associated steatohepatitis, a serious form of fatty liver disease. The use of semaglutide, a ...
Ozempic may have neurologic benefit despite Alzheimer's setback, large study suggests ...
A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...
SAN FRANCISCO — In patients with both type 2 diabetes and moderate chronic kidney disease (CKD), the investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide (Novo Nordisk) ...
This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. What Happens If You Use Expired Semaglutide? Wondering what ...
A new-ish diabetes and obesity drug that can help users shed pounds is making big waves on social media and rippling through celebrity gossip echo chambers — but its popularity is also driving a ...